Pr8/22 Cell Line
Invented at Cancer Research UK Manchester Institute
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 153248 |
| Parental Line | P388 |
| Host | Mouse |
| Tissue | Lymphatic Tissue |
| Disease Keywords | Drug resistant |
| Model | Tumour line |
| Relevance | The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm originating in DBA/2 mouse and converted to ascitic form in the first mouse transfer. Pr8/22 is resistant to daunorubicin and is multi drug resistant (MDR). Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged. |
| Production Details | The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm. |
| Conditional | No |
| Research Area | Cancer, DNA Damage and Repair, Drug Discovery & Development |
| Growth/Phenotype Keywords | Suspension |
| Recommended Growing Conditions | Sub-culture routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage.Culture Medium: RPMI 1640 + 2mM Glutamine + 10% Horse Serum (HS); treat once a month with 0.1µM Daunorubicin. |
| Cellosaurus ID | CVCL_4276 |
References: 2 entries
McGown et al. 1983. Cancer Chemother Pharmacol. 11(2):113-6. PMID: 6627597.
Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures.
Europe PMC ID: 6627597
Add a reference
References: 2 entries
McGown et al. 1983. Cancer Chemother Pharmacol. 11(2):113-6. PMID: 6627597.
Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures.
Add a reference
